A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis

BACKGROUND: Alemtuzumab (ALZ) is a pulsed immune reconstitution therapy for multiple sclerosis (MS). OBJECTIVE: To assess basic characteristics, therapeutic effects, and prognostic biomarkers on clinical and imaging parameters of disease activity for relapsing–remitting MS (RRMS) patients selected f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandgren, Sofia, Novakova, Lenka, Nordin, Anna, Axelsson, Markus, Malmeström, Clas, Zetterberg, Henrik, Lycke, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551138/
https://www.ncbi.nlm.nih.gov/pubmed/37808497
http://dx.doi.org/10.3389/fneur.2023.1265354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551138/
https://www.ncbi.nlm.nih.gov/pubmed/37808497
http://dx.doi.org/10.3389/fneur.2023.1265354

Ejemplares similares